FDA Prioritizes New Hepatitis C Drug
Is Johnson & Johnson's simeprevir destined to be the first next-gen hepatitis-C drug.
Big Pharma's Biggest Winners
A Fool recaps first-quarter earnings bright spots around the pharmaceutical industry.
Vivus Increases Board to 9 Members
The pharma company announces its second and third new board members in two weeks.